BioVie (NASDAQ:BIVI) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of BioVie (NASDAQ:BIVI) from a hold rating to a buy rating in a research note released on Monday morning, Zacks.com reports. They currently have $5.75 target price on the stock.